IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes - PubMed (original) (raw)
IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes
Ilaria Peluso et al. J Immunol. 2007.
Abstract
High expression of IL-21 and/or IL-21R has been described in T cell-mediated inflammatory diseases characterized by defects of counterregulatory mechanisms. CD4(+)CD25(+) regulatory T cells (Treg) are a T cell subset involved in the control of the immune responses. A diminished ability of these cells to inhibit T cell activation has been documented in immune-inflammatory diseases, raising the possibility that inflammatory stimuli can block the regulatory properties of Treg. We therefore examined whether IL-21 controls CD4(+)CD25(+) T cell function. We demonstrate in this study that IL-21 markedly enhances the proliferation of human CD4(+)CD25(-) T cells and counteracts the suppressive activities of CD4(+)CD25(+) T cells on CD4(+)CD25(-) T cells without affecting the percentage of Foxp3(+) cells or survival of Treg. Additionally, CD4(+)CD25(+) T cells induced in the presence of IL-21 maintain the ability to suppress alloresponses. Notably, IL-21 enhances the growth of CD8(+)CD25(-) T cells but does not revert the CD4(+)CD25(+) T cell-mediated suppression of this cell type, indicating that IL-21 makes CD4(+) T cells resistant to suppression rather than inhibiting CD4(+)CD25(+) T cell activity. Finally, we show that IL-2, IL-7, and IL-15, but not IL-21, reverse the anergic phenotype of CD4(+)CD25(+) T cells. Data indicate that IL-21 renders human CD4(+)CD25(-) T cells resistant to Treg-mediated suppression and suggest a novel mechanism by which IL-21 could augment T cell-activated responses in human immune-inflammatory diseases.
Similar articles
- A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment.
Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL. Strauss L, et al. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4345-54. doi: 10.1158/1078-0432.CCR-07-0472. Clin Cancer Res. 2007. PMID: 17671115 - Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells.
Kessel A, Haj T, Peri R, Snir A, Melamed D, Sabo E, Toubi E. Kessel A, et al. Autoimmun Rev. 2012 Jul;11(9):670-7. doi: 10.1016/j.autrev.2011.11.018. Epub 2011 Dec 2. Autoimmun Rev. 2012. PMID: 22155204 - Forced overexpression of either of the two common human Foxp3 isoforms can induce regulatory T cells from CD4(+)CD25(-) cells.
Aarts-Riemens T, Emmelot ME, Verdonck LF, Mutis T. Aarts-Riemens T, et al. Eur J Immunol. 2008 May;38(5):1381-90. doi: 10.1002/eji.200737590. Eur J Immunol. 2008. PMID: 18412171 - CD4+CD25+ T Regulatory Cells in Transplantation Tolerance: 25 Years On.
Hall BM. Hall BM. Transplantation. 2016 Dec;100(12):2533-2547. doi: 10.1097/TP.0000000000001436. Transplantation. 2016. PMID: 27861285 Review. - Interleukin-21 in immune and allergic diseases.
Sarra M, Cupi ML, Pallone F, Monteleone G. Sarra M, et al. Inflamm Allergy Drug Targets. 2012 Aug 1;11(4):313-9. doi: 10.2174/187152812800959040. Inflamm Allergy Drug Targets. 2012. PMID: 22533549 Review.
Cited by
- Enhanced abscopal anti-tumor response via a triple combination of thermal ablation, IL-21, and PD-1 inhibition therapy.
Wu S, Jiang H, Fang Z, Wu Y, Jiao J, Fang W, Wu Y, Lang Y, Chen N, Zhong Z, Chen L, Zheng X, Lu B, Jiang J. Wu S, et al. Cancer Immunol Immunother. 2024 Jun 4;73(8):138. doi: 10.1007/s00262-024-03718-1. Cancer Immunol Immunother. 2024. PMID: 38833177 Free PMC article. - Therapeutic potential of interleukin-21 in cancer.
Isvoranu G, Chiritoiu-Butnaru M. Isvoranu G, et al. Front Immunol. 2024 Apr 4;15:1369743. doi: 10.3389/fimmu.2024.1369743. eCollection 2024. Front Immunol. 2024. PMID: 38638431 Free PMC article. Review. - The IL-21/IL-21R signaling axis regulates CD4+ T-cell responsiveness to IL-12 to promote bacterial-induced colitis.
Solaymani-Mohammadi S. Solaymani-Mohammadi S. J Leukoc Biol. 2024 Oct 1;116(4):726-737. doi: 10.1093/jleuko/qiae069. J Leukoc Biol. 2024. PMID: 38498592 Free PMC article. - Therapeutic effect of ofatumumab in patients with myasthenia gravis: immunoregulation of follicular T helper cells and T helper type 17 cells.
Li S, Zhang Z, Liu Z. Li S, et al. Front Neurol. 2023 Dec 11;14:1278250. doi: 10.3389/fneur.2023.1278250. eCollection 2023. Front Neurol. 2023. PMID: 38146439 Free PMC article. - Negative impact of Interleukin-9 on synovial regulatory T cells in rheumatoid arthritis.
Chakraborty S, Gupta R, Kubatzky KF, Kar S, Kraus FV, Souto-Carneiro MM, Lorenz HM, Kumar P, Kumar V, Mitra DK. Chakraborty S, et al. Clin Immunol. 2023 Dec;257:109814. doi: 10.1016/j.clim.2023.109814. Epub 2023 Oct 23. Clin Immunol. 2023. PMID: 37879380 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials